MDxHealth SA
Molecular diagnostic tests for prostate cancer risk stratification using genomic analysis
- Sector
- Medtech
- Headquarters
- Herstal, C9
- Latest Form D
- $5M, Aug 2022
- Total capital
- $5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $5M
- 1 Form D · last Aug 2022
- 50 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 7 pending · first 2016
- Rank in peer group#22 of 160
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 160 peers
Line = medianMedtech · Instrument
- Granted patents#22 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Donnie M. Hardison Jr.DirectorNamed in SEC Form D filings
- Eric BednarskiDirectorNamed in SEC Form D filings
- Hilde M. WindelsDirectorNamed in SEC Form D filings
- Jan M. PensaertDirectorNamed in SEC Form D filings
- John M. BellanoExecutive OfficerNamed in SEC Form D filings
- Joseph M. SolleeExecutive OfficerNamed in SEC Form D filings
Show all 11 people
- Koen HoffmanDirectorNamed in SEC Form D filings
- Lieve M. VerplanckeDirectorNamed in SEC Form D filings
- Michael K. McGarrityExecutive Officer, DirectorNamed in SEC Form D filings
- Regine K. SlagmulderDirectorNamed in SEC Form D filings
- Ron M. KalfusExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 13- PendingMgmt Epigenetic Deep-sequencing AssayUSPTOApplication 18999999
- PendingMethod for Using Gene Expression to Determine Prognosis of Prostate CancerUSPTOApplication 18782817
- PendingMethod for Predicting and Treating Clinically Significant Prostate CancerUSPTOApplication 18233216
Show all 13 patent records
- Mgmt Epigenetic Deep-sequencing AssayJul 3, 2025 · Application 18999999Pending
- Method for Using Gene Expression to Determine Prognosis of Prostate CancerApr 24, 2025 · Application 18782817Pending
- Method for Predicting and Treating Clinically Significant Prostate CancerMar 7, 2024 · Application 18233216Pending
- Method For Predicting And Treating Clinically Significant Prostate CancerSep 26, 2023 · US 11,767,563Granted
- Method For Using Gene Expression To Determine Prognosis Of Prostate CancerDec 15, 2022 · Application 17820987Pending
- Algorithms and Methods for Assessing Late Clinical Endpoints in Prostate CancerFeb 6, 2020 · Application 16485203Pending
- Mgmt Epigenetic Deep-sequencing AssayJan 9, 2020 · Application 16495070Pending
- Methods And Kits For Identifying And Adjusting For Bias In Sequencing Of Polynucleotide SamplesNov 6, 2018 · US 10,119,166Granted
- Method for Determining the Methylation Status of the Promoter Region of the TWIST1 Gene in Genomic DNA from Bladder CellsOct 30, 2018 · US 10,113,202Granted
- Methylation Detection Of The Mgmt PromoterAug 21, 2018 · US 10,053,724Granted
- Methods Of Detecting Mutations In Braf And Epigenetic ChangesMar 28, 2017 · US 9,605,312Granted
- Detection and Prognosis of Cervical CancerJun 21, 2016 · US 9,371,569Granted
- Methylation Markers Predictive For Drug ResponseOct 15, 2015 · Application 14438742Pending
Related companies, and why
- Spinal Surgical Strategies, Inc.Similar federal contract value in Medtech · null in contracts
- Medaica Inc.Similar federal contract value in Medtech · null in contracts
- Renew Digital Holdings, LLCSimilar federal contract value in Medtech · null in contracts
- MuscleSound, Inc.Similar federal contract value in Medtech · null in contracts
- Techcyte, Inc.Similar federal contract value in Medtech · null in contracts
- PASCALL Systems, IncorporatedSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .